Global Atopic Dermatitis (AD) Market: Analysis By Therapy (Biologic, Oral, Topical, Photo), End User, Pipeline, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024) 2022-2030

  • Product Code:
    RP-ID-10246008
  • Published Date:
    28 Sep 2021
  • Region:
    Global
  • Pages:
    224
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-29

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

The Research Report is Updated with 2020 Base Year, 2021 Estimated year and Forecast till 2030 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2020 as base year, 2021 as estimated year and forecast to 2030. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

" By the end of 2021, the global atopic dermatitis market is estimated to be valued at ~USD 12 billion, thereby marking a CAGR of more than 15% over the period 2022-2030. Rising pollution levels, accelerating urbanization, unhealthy lifestyles, and the increase in the number of allergies supported by hygiene assumptions are factors that contribute to the higher global prevalence of atopic dermatitis. It is the most common form of eczema and there is no permanent cure, but new treatments are being introduced on the market to control the itching and discomfort

 

associated with AD. Topical therapy is the highlight of the AD market because it is easy to apply on the skin and has better results. However, with the emergence of the first Dupixent targeted biological therapy (a cooperation between Sanofi and Regeneron) in major regions of the world in 2017, the revenue of the AD market has increased significantly and is expected to increase exponentially during the forecast period . 


In addition, the atopic dermatitis market is also expected to grow due to the well-designed product portfolio of pharmaceutical companies. In addition, since the number of patient visits for AD, asthma, allergies, and hay fever is expected to increase during the prognosis period, end-user hospitals may experience peak growth.
Among these regions, the Asia-Pacific region, followed by the Americas and Europe, will have the highest growth rate due to the increase in the prevalence and per capita expenditure of medical care. Report Scope This report analyzes the atopic dermatitis market by treatment segment (biological treatment, topical treatment, oral treatment, phototherapy). 

 

The report assesses the atopic dermatitis market by end users (hospitals, clinics, research laboratories). The global atopic dermatitis market has been analyzed by region (Americas, Europe, Asia Pacific, rest of the world) and country (United States, Canada, Mexico, Brazil, Germany, United Kingdom, Japan, China, India, Australia). 

 

The key insights of the report have been presented through the SWOT framework and market attractiveness charts. Regions, treatments, and end users have already proposed market appeal. In addition, the report analyzes the main opportunities, trends, driving factors and challenges of the industry. The report analyzed in detail the drugs being developed to treat atopic dermatitis. Acquisition and development of new products. 

 

The companies analyzed in the report include Sanofi, Regeneron, Pfizer, Allergan, AbbVie, Leo Pharmaceuticals, Eli Lilly, Aclaris, Anaptys Bio, Dermira. The report introduces the historical period and forecast period from 2014 to 2030. Market analysis of atopic dermatitis. 

 

 MAIN TARGET AUDIENCES : 


Pharmaceutical companies, consulting companies, medical professionals, regulatory agencies. "
 


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Sanofi, Regeneron, Pfizer, Allergan, Abbvie, Leo Pharma, Lilly, Aclaris, Anaptys Bio, Dermira

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports